for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Syngene International Ltd

SYNN.NS

Latest Trade

314.55INR

Change

4.60(+1.48%)

Volume

51,795

Today's Range

309.90

 - 

315.90

52 Week Range

250.05

 - 

369.00

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
309.95
Open
313.60
Volume
51,795
3M AVG Volume
2.55
Today's High
315.90
Today's Low
309.90
52 Week High
369.00
52 Week Low
250.05
Shares Out (MIL)
396.05
Market Cap (MIL)
122,819.80
Forward P/E
31.41
Dividend (Yield %)
0.16

Latest Developments

More

India's Syngene International Dec-Qtr Profit Rises

Syngene International Expands Collaboration With Baxter Healthcare Corp

India's Biocon, Biocon Research Cut Stake In Syngene International

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Syngene International Ltd

Syngene International Limited is a contract research company. The Company is engaged in providing contract research and manufacturing services in early-stage drug discovery and development to pharmaceutical and biotechnology companies. Its services include discovery chemistry and biology services, toxicology, pharmaceutical development, process development/manufacture of intermediates, active pharmaceutical ingredients and bio-therapeutics. Its services encompass integrated, discovery and development services for novel molecular entities (NMEs) across industrial sectors, including pharmaceutical, biopharmaceutical and biotechnology, among others. It specializes in conducting discovery (from hit to candidate selection), development (including pre-clinical and clinical studies, analytical and bio-analytical evaluation, and stability studies) and manufacturing (scale-up, pre-clinical and manufacturing supplies). It serves clients ranging from multinational corporations to start-ups.

Industry

Biotechnology & Drugs

Contact Info

+91.80.67758781

http://www.syngeneintl.com/

Executive Leadership

Kiran Mazumdar Shaw

Executive Chairman of the Board, Managing Director

Jonathan Hunt

Chief Executive Officer, Whole Time Director

M. B. Chinappa

Chief Financial Officer

Manoj Nerurkar

Chief Operating Officer

Priyadarshini Mahapatra

Compliance Officer, Company Secretary

Key Stats

2.83 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2017

12.0K

2018

14.2K

2019

18.3K

2020(E)

21.0K
EPS (INR)

2017

7.275

2018

7.715

2019

8.360

2020(E)

9.867
Price To Earnings (TTM)
36.49
Price To Sales (TTM)
6.67
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
24.00
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

BRIEF-India's Syngene International Dec-Qtr Profit Rises

* DEC QUARTER PROFIT 819 MILLION RUPEES VERSUS PROFIT 744 MILLION RUPEES YEAR AGO

BRIEF-Syngene International ‍expands collaboration with Bristol-Myers Squibb​

* Nnext phase of partnership will see addition of facility to support future Bristol-Myers Squibb research and development operations Source text: http://bit.ly/2iT2tvz Further company coverage:

BRIEF-India's Syngene International Sept-qtr profit rises 3 pct

* Sept quarter net profit 769 million rupees versus profit of 747 million rupees last year

BRIEF-Syngene International confident that impact of fire incident of last yr to taper off in coming qtrs

* Says confident that the impact of the fire incident of last year will taper off in the coming quarters

BRIEF-India's Syngene International June-qtr profit rises about 4 pct

* June quarter profit 620 million rupees versus 598 million rupees last year

BRIEF-Syngene International & Herbalife partner to establish nutrition R&D lab in India

* Says Herbalife nutrition partners with Syngene to establish nutrition research and development lab in India

BRIEF-Syngene International Dec qtr profit falls about 4 pct

* Syngene International Ltd - dec quarter net profit 744 million rupees

BRIEF-Syngene International Sept qtr profit up about 54 pct

* Syngene International Ltd - sept quarter net profit 747 million rupees

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up